Biosapien - The Revolutionary Cancer Platform Developer - Announces Two, World-Class US Manufacturing Partners: Roswell Park and BA Sciences

SAN DIEGO, July 1, 2026 /PRNewswire/ -- BioSapien, the pioneering biotech company, announces two world-class US manufacturing partners, ahead of imminent Phase I clinical trials for MediChip™, its revolutionary localised cancer drug delivery platform.

About BioSapien

BioSapien Inc. is a venture-backed biotechnology company focused on innovative therapies to transform patient care. The company invented MediChip™: a patented treatment that early research has shown can reduce the system-wide side effects of cancer chemotherapy treatments.

Potential For Stage III, IV Pancreatic Cancer

Ahead of imminent Phase I clinical trials in the UAE, BioSapien has completed the first clinical batch of production of its GMP grade MediChips, at Roswell Park. Production took place in an ISO-7 cleanroom space within the Roswell Park GMP Engineering & Cell Manufacturing (GEM) Facility leased by Roswell Park to BioSapien – the first external company Roswell Park has ever rented out cleanroom space to. Further production of clinical MediChips and intermediates will take place at Roswell Park.

BA Sciences has validated all GMP analytics required by BioSapien for a clinical product, and carried out those analytics on the produced MediChips. Other activity by BA Sciences includes stability studies to confirm the longevity of MediChip™ and to extend its shelf life.

Biosapien a biotech company has announced it has raised $1.8M in seed round funding led by global venture capital investor SOSV.

BioSapien, a biotech company has announced it has raised $1.8M in seed round funding led by global venture capital investor SOSV. Co-investors in the round include Hikma Ventures, Microventures, Infinity Capital Ventures, JPIN VCATS, Side Door Ventures, and other high-net worth angels and investors (Additional investors listed below)*.

In addition to the seed round funding, a non-dilutive grant of $256K from the National Science Foundation will accelerate the development of BioSapien’s patented product, MediChip™: a 3D printed biodegradable mesh chip designed to deliver cancer drugs directly to the tumor site while reducing side effects.

“It’s great to have the support of these esteemed investors in BioSapien,” says Dr. Khatija Ali, CEO and co-founder of BioSapien. “The seed round funds will advance development of MediChip™ and give access to global distribution channels and manufacturing.

Chemotherapy can cause devastating side effects for patients. MediChip™ is designed to deliver cancer drugs straight to hard-to-reach tumor sites, for increased efficacy with reduced toxicity.”

MediChip™ is a novel biodegradable drug delivery platform designed to precisely administer any type of FDA-approved drug, locally and in a sustained manner. Pre-clinical research shows that in comparison to systemic chemotherapy, MediChip™ mitigates systemic side-effects through localized controlled release.

For cancer indications, it has the potential to improve the patient’s quality of care and life. It is designed to be a first-line treatment option for stage III locally advanced gastrointestinal cancer patients during surgery for adjuvant chemotherapy delivery. MediChip™ was granted its patent in February 2021 with a priority date of December 21, 2018.

‍